Protagonist Therapeutics PTGX Proceeds From Exercise Of Warrants In Exchange For Issuance Of Pre Funded Warrants
Proceeds From Exercise Of Warrants In Exchange For Issuance Of Pre Funded Warrants at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept ptgx:ProceedsFromExerciseOfWarrantsInExchangeForIssuanceOfPreFundedWarrants.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's proceeds from exercise of warrants in exchange for issuance of pre funded warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's proceeds from exercise of warrants in exchange for issuance of pre funded warrants?
- Protagonist Therapeutics (PTGX) reported proceeds from exercise of warrants in exchange for issuance of pre funded warrants of $34.4M in Q3 2023.
- What does proceeds from exercise of warrants in exchange for issuance of pre funded warrants mean?
- This captures the cash proceeds received when warrants are exercised, specifically in scenarios involving the exchange for pre-funded warrants. It represents a source of capital generated through the conversion of derivative instruments into equity. This metric helps investors evaluate the company's ability to raise capital through existing financial instruments and the resulting dilution impact.